Solventum Corporation (SOLV) — Q2 2026 Earnings Preview
Company | Solventum Corporation |
Ticker | SOLV |
Upcoming Earnings Date | August 5, 2026 (Q2 2026) |
Preparation Date | August 4, 2026 |
Last Earnings | Q1 2026 — Reported May 5, 2026 (Beat on Revenue & EPS) |
1. Earnings Preview
Key Takeaway: The setup into Q2 2026 is intentionally distorted by a known ERP-related pull-forward of over $100 million in distributor orders from Q3 into Q2; consensus already reflects this tailwind (~7% organic growth estimate vs. ~2% underlying), so the real swing factor is whether gross margin can hold near Q1’s 56.4% level and whether EPS can sustain the beat-and-raise cadence management has established.
Heading into Q2 2026, Solventum’s reported results will be materially inflated by the ERP cutover pull-forward strategy: management guided analysts to expect over $100 million of incremental distributor orders in Q2 that will largely reverse in Q3, primarily impacting IPSS and Dental segments. Consensus has absorbed this guidance, with Q2 organic growth estimated at ~7% vs. a normalized underlying rate closer to 4–5%, making the reported top-line number a poor signal of business health. The more meaningful read will be on gross margin trajectory (management guided “slightly below Q1” at ~56% for remaining quarters), operating expense step-down (guided to decline sequentially from Q1’s $740M), and EPS delivery against the raised high-end guidance of $6.40–$6.60 for the full year. The stock has surged +27% since Q1 earnings vs. SPY +7%, pricing in significant execution credibility, which raises the bar for a positive reaction. The key wildcard is Trian’s activist pressure — any incremental commentary on HIS segment separation or portfolio actions could be a larger catalyst than the underlying quarterly numbers.
2. KPIs & Consensus Expectations
Key Takeaway: Consensus is a deliberately elevated bar on revenue (reflecting the $100M+ pull-forward) but a reasonable bar on EPS and margins; the bigger swing factor is gross margin — any outperformance vs. the guided ~56% level would be the most meaningful positive signal, as it was in Q1.
Table 1 — Q2 2026 Current Quarter Snapshot
KPI | Q1 2026 Actual | Q2 2025 Actual (Prior Year) | Q2 2026 Consensus Estimate | YoY Change | FY 2026 Guidance | Consensus vs. Guidance |
Total Revenue ($M) | $2,007 | $2,161 | $2,155 | -0.3% | ~$8,194 (FY) | In line |
Organic Revenue Growth (%) | 2.1% | 2.8% | ~7.0% | +420 bps | 3–5% (FY guide) | Above (ERP pull-fwd) |
EPS — Diluted Operating ($) | $1.48 | $1.69 | $1.90 | +12.4% | $6.40–$6.60 (high end) | ~+15% above Q2’25 run-rate; in line with raised guide |
Gross Profit — Operating ($M) | $1,133 | $1,209 | $1,205 | -0.3% | ~56% gross margin guided | In line with guidance |
Operating Income — Operating ($M) | $392 | $474 | $489 | +3.2% | 21%–21.5% op. margin (FY) | In line |
MedSurg Revenue ($M) | $1,234 | $1,218 | $1,347 | +10.6% | N/A (segment) | Elevated (ERP pull-fwd) |
Dental Solutions Revenue ($M) | $354 | $338 | $378 | +11.8% | N/A (segment) | Elevated (ERP pull-fwd) |
Health Information Systems Revenue ($M) | $342 | $339 | $353 | +4.1% | ~4% growth (Street est.) | In line |
Free Cash Flow ($M) | -$273 | $59 | $57 | -3.4% | Improving H2 (FY guide) | In line |
Source: Visible Alpha Consensus and Actuals Data. Note: Q2 2026 organic growth consensus (~7%) is materially elevated vs. underlying business trend (~4–5%) due to the ERP-related pull-forward of $100M+ in distributor orders from Q3 into Q2. Management explicitly advised analysts not to adjust full-year models based on Q2 phasing.
Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)
Top 2 KPIs: Organic Revenue Growth (%) and EPS — Diluted Operating ($)
Quarter | KPI | Reported | Consensus | Surprise % | Result |
Q1 2026 | Organic Growth | 2.1% | 0.95% | +121 bps | Beat |
Q1 2026 | EPS — Op. | $1.48 | $1.37 | +7.9% | Beat |
Q4 2025 | Organic Growth | 3.5% | 2.1% | +140 bps | Beat |
Q4 2025 | EPS — Op. | $1.57 | $1.50 | +4.7% | Beat |
Q3 2025 | Organic Growth | 2.7% | 0.9% | +180 bps | Beat |
Q3 2025 | EPS — Op. | $1.50 | $1.43 | +4.9% | Beat |
Q2 2025 | Organic Growth | 2.8% | 1.6% | +120 bps | Beat |
Q2 2025 | EPS — Op. | $1.69 | $1.45 | +16.5% | Beat |
Pattern: SOLV has beaten consensus on both organic growth and operating EPS in every quarter shown — a consistent beat-and-raise cadence across the last 4 reported quarters, with EPS beats averaging ~8–17% above consensus and organic growth beats averaging 120–180 bps above estimates. The bar has been consistently set low by the Street, though the stock’s +27% post-Q1 rally means the market is now pricing in continued outperformance.
Source: Visible Alpha Consensus and Actuals Data.
3. Guidance & Commentary Evolution
Key Takeaway: Management’s posture has shifted more confident since Q1 earnings — EPS guidance was raised to the high end of the $6.40–$6.60 range, while organic growth and FCF guidance were maintained; tone at the Jefferies (June 3) and BofA (May 13) conferences was consistently upbeat, with management expressing “very confident” language on full-year delivery.
Metric | Initial Guidance (Q1 2026 Earnings Call — May 5, 2026) | Revised Guidance | Current Consensus | Note |
FY 2026 Organic Revenue Growth | 3–5% (maintained from Q4 2025 call) | — | ~2.8% (FY consensus) | Unchanged; management “very confident” at Jefferies (Jun 3). Consensus below midpoint due to Q3 pull-forward reversal. |
FY 2026 EPS — Diluted Operating | $6.40–$6.60 (toward high end) | ↑ Raised to high end at Q1 earnings (May 5, 2026) | $6.55 | ↑ Raised at Q1 earnings; strong Q1 beat drove upgrade. Jefferies (Jun 3) confirmed no further change. |
FY 2026 Operating Margin | 21%–21.5% (+50–100 bps YoY) | — | ~21.1% (FY consensus) | Unchanged; Q1 at 19.5% (seasonal low). Gross margin guided “slightly below Q1” (~56%) for remaining quarters. |
FY 2026 Free Cash Flow | Improving vs. 2025; Q4 strongest quarter | — | ~$214M (FY consensus) | Unchanged; FCF depressed by transient separation costs; management targets ~$1B normalized run-rate by 2027–28. |
Tariff Headwind | $100M–$120M annual headwind (fully embedded in guidance) | — | N/A | Unchanged; Jefferies (Jun 3) confirmed holding estimate. Upside if tariffs more favorable; downside if worse. |
Q2 2026 Revenue Phasing | Over $100M pull-forward into Q2 from Q3 (ERP mitigation) | — | ~$2,155M Q2 consensus | Confirmed at Jefferies (Jun 3) and BofA (May 13). Management advised not to adjust full-year models. |
Share Repurchase | Accelerating; $1B Board authorization; 923K shares / $67M in Q1 | — | N/A | Jefferies (Jun 3): management confirmed actively accelerating repurchases at lower stock price levels. |
4. Guidance vs. Estimate Revision Tracker
Key Takeaway: Estimates for Q2 2026 have moved modestly higher since Q1 earnings (EPS +1.1%, revenue flat), tracking management’s raised EPS guidance; for the full year, consensus is essentially unchanged, suggesting the Street is treating the Q2 pull-forward as a wash and focusing on the underlying 3–5% organic growth trajectory. The gap between FY consensus (~2.8% organic) and guidance midpoint (4%) represents a potential cushion if execution continues.
KPI (Period) | Estimate ~5 Days Post Q1 Earnings (as of May 12, 2026) | Current Consensus | Estimate Δ (%) | Initial Guidance (Q1 Earnings Call) | Current Guidance | Guidance Δ | Consensus vs. Guidance (%) |
Total Revenue — Q2 2026 ($M) | $2,152 | $2,155 | +0.1% | Pull-forward of $100M+ into Q2 | Unchanged | — | In line with pull-forward guidance |
Organic Growth — Q2 2026 (%) | ~6.8% | ~7.0% | +20 bps | Elevated due to ERP pull-fwd | Unchanged | — | Reflects pull-forward; underlying ~4–5% |
EPS — Diluted Operating — Q2 2026 ($) | $1.88 | $1.90 | +1.1% | Toward high end of $6.40–$6.60 FY range | Unchanged (high end) | — | In line with raised guidance |
Total Revenue — FY 2026 ($M) | $8,194 | $8,194 | Flat | 3–5% organic growth | Unchanged | — | Consensus ~2.8% organic vs. 4% midpoint — cushion |
EPS — Diluted Operating — FY 2026 ($) | $6.55 | $6.55 | Flat | $6.40–$6.60 (toward high end) | Raised to high end | ↑ Raised | Consensus at high end of range |
Source: Visible Alpha Consensus and Actuals Data. As-of date for baseline: May 12, 2026 (~5 trading days post Q1 earnings on May 5, 2026).
Estimates have been remarkably stable since Q1 earnings, with the Street essentially accepting management’s framing that Q2/Q3 are a wash due to ERP phasing and focusing on the full-year trajectory. The FY consensus organic growth of ~2.8% sitting below the 4% guidance midpoint represents a meaningful cushion if SOLV continues its beat-and-raise pattern.
5. Stock Performance
Key Takeaway: SOLV has dramatically outperformed since Q1 earnings (+27.4% vs. SPY +6.6%), driven by a combination of multiple expansion and improving earnings credibility; the stock’s re-rating reflects growing confidence in the transformation story, but the elevated entry point raises the bar for a positive Q2 reaction.
SOLV vs. SPY (S&P 500 ETF) — Indexed to 100 at Q1 2026 Earnings Date (May 5, 2026). SOLV: +27.4%; SPY: +6.6% through August 4, 2026. Sector ETF used: SPY (S&P 500 broad market). Source: Stock Price Data.
Performance Narrative: SOLV opened Q1 earnings day at $69.04 and rallied steadily through mid-June, reaching a peak near $82 on June 4 following the Jefferies Healthcare Conference (June 3) where management reiterated confidence in full-year guidance and confirmed accelerating share repurchases. The stock pulled back through late June and early July (range $73–$79) before a sharp re-acceleration in late July, closing at $88.07 on August 3 — the highest level since the post-Q1 rally. The outperformance vs. SPY (+27.4% vs. +6.6%) reflects both multiple expansion and the market’s growing confidence in SOLV’s transformation execution. The Jefferies conference on June 3 was the most notable catalyst, driving a +5.4% single-day move. The stock’s strong pre-earnings run means the market is pricing in continued delivery, raising the risk of a “sell the news” reaction if Q2 results merely meet (rather than beat) expectations.
6. Material News & Developments
Key Takeaway: The most important development since Q1 earnings is the combination of Trian’s escalating activist pressure and management’s accelerating share repurchase program — together these create a near-term catalyst for portfolio action (HIS separation) that could be more impactful than the quarterly numbers themselves.
- August 5, 2026 — Q2 2026 Earnings Release (Today): SOLV reports Q2 2026 results. Key focus areas: gross margin vs. guided ~56%, EPS delivery vs. $1.90 consensus, and any updated commentary on HIS segment strategy given Trian pressure. Management will also need to address the Q3 pull-forward reversal and its impact on H2 guidance.
- July 20, 2026 — New Chief Accounting Officer Appointed: Solventum named Neil Zieselman as Chief Accounting Officer (8-K filed). Replaces Mary T. Wilcox, who had been serving in the role. Routine leadership transition; no material financial implication flagged.
- July 15, 2026 — Q2 Earnings Date Announced: Solventum confirmed August 5, 2026 as the Q2 2026 earnings date via press release. Routine disclosure.
- June 3, 2026 — Jefferies Global Healthcare Conference: Management reiterated full-year guidance as unchanged, confirmed EPS raised to high end of $6.40–$6.60 range, and provided additional color on the $100M+ Q2 pull-forward. Importantly, management confirmed they are actively accelerating share repurchases at current lower stock price levels. Tuck-in M&A defined as up to ~$1B with preference for hundreds of millions or less. Stock rose +5.4% on the day. Implication: management’s confidence and buyback acceleration are bullish signals heading into Q2.
- May 13, 2026 — Bank of America Global Healthcare Conference: HIS segment president Garri Garrison provided detailed competitive positioning commentary, emphasizing AI as an advantage, 75%+ U.S. hospital market penetration, and stability of the business (no tariff, oil, or supply chain exposure). Management expressed excitement about the rest of 2026. Implication: HIS segment is being actively marketed as a high-quality, stable asset — relevant context for Trian’s separation push.
- Late April 2026 — Trian Fund Management Activist Escalation: Nelson Peltz’s Trian Fund Management (~5% owner) publicly escalated demands, calling for immediate HIS segment separation, overhead rightsizing, and improved capital allocation. Management has engaged but defended transformation track record. Implication: this is the single largest portfolio catalyst — any Q2 commentary on HIS strategic review could move the stock more than the quarterly numbers.
- May 5, 2026 — Q1 2026 Earnings Beat: Beat on both revenue and EPS; gross margin expanded 80 bps YoY to 56.4% despite tariff headwinds; EPS of $1.48 (+11% YoY) beat consensus by ~8%; EPS guidance raised to high end of $6.40–$6.60 range; share repurchase program initiated (923K shares / $67M in Q1); TSA exits surpassed 50% milestone. Implication: established the beat-and-raise cadence that has driven the stock’s +27% post-earnings rally.
- Ongoing — ERP Cutover (US/Canada, Q3 2026): The US and Canada ERP cutover is the last major ERP event, planned for Q3. The $100M+ pull-forward into Q2 is the mitigation strategy. Management expects 90% of TSAs exited by year-end 2026. Implication: Q3 will show a mirror-image revenue headwind; investors should focus on full-year guidance, not quarterly phasing.
- Ongoing — Tariff Headwind ($100M–$120M Annual): Fully embedded in guidance. Q1 came in at the high end of the quarterly range. No tariff refunds assumed in guidance (unlike peers BSX, ISRG, GEHC, SYK who recognized refunds in Q2). Implication: if tariff refunds materialize for SOLV in Q2, this could be an upside surprise to EPS.
- Ongoing — Acera Acquisition Integration: First tuck-in acquisition (NPWT space) grew “very strongly” in Q1, ahead of management’s own internal expectations. Contributed $28M to Q1 MedSurg revenue. Implication: validates the tuck-in M&A playbook and supports MedSurg growth trajectory.
7. Insider Transaction Activity
Key Takeaway: No open-market buys or discretionary sells were filed in the post-Q1 window — all transactions are routine RSU vesting events (code M = exercise/conversion) with associated tax withholding shares (code F = shares withheld for taxes), plus director RSU grants (code A). No insider has made a discretionary open-market purchase or sale since Q1 earnings, which is neither a bullish nor bearish signal given the routine nature of the activity.
Name | Title | Transaction Type | Shares | Date | Note |
Bryan C. Hanson | CEO & Director | RSU Vesting (M) + Tax Withholding (F) | 34,315 vested; 13,503 withheld | May 13, 2026 | Routine RSU vest; tax withholding shares disposed (obligation-driven, not discretionary) |
Wayde D. McMillan | CFO | RSU Vesting (M) + Tax Withholding (F) | 9,503 vested; 4,404 withheld | May 13, 2026 | Routine RSU vest; tax withholding shares disposed (obligation-driven, not discretionary) |
Tammy L. Gomez | Chief Human Resources Officer | RSU Vesting (M) + Tax Withholding (F) | 3,960 vested; 1,668 withheld | May 13, 2026 | Routine RSU vest; tax withholding shares disposed (obligation-driven, not discretionary) |
Paul S. Harrington | Chief Supply Chain Officer | RSU Vesting (M) + Tax Withholding (F) | 3,960 vested; 1,678 withheld | May 13, 2026 | Routine RSU vest; tax withholding shares disposed (obligation-driven, not discretionary) |
Marcela A. Kirberger | Chief Legal Affairs Officer | RSU Vesting (M) + Tax Withholding (F) | 4,488 vested; 1,952 withheld | May 13, 2026 | Routine RSU vest; tax withholding shares disposed (obligation-driven, not discretionary) |
Amy Landucci | Chief Information Officer | RSU Vesting (M) + Tax Withholding (F) | 4,422 vested; 2,017 withheld | May 13, 2026 | Routine RSU vest; tax withholding shares disposed (obligation-driven, not discretionary) |
11 Directors (incl. Alban, Cox, DeVore, Edwards, Eisenberg, Harris, May, Mily, Weiland, Wendell, Wilson) | Board Directors | RSU Grant (A) | 3,300–4,848 each | May 15, 2026 | Annual director RSU grant; routine compensation award, not a market signal |
Source: SEC Form 4 Filings. All transactions are code M (RSU vesting/conversion) or code F (tax withholding) or code A (grant/award). No open-market buys (code P) or discretionary sells (code S) were filed in the period. The absence of discretionary insider buying despite the stock’s +27% rally since Q1 earnings is notable but not unusual given the proximity to earnings blackout periods.
8. Peer Commentaries — Q2 2026 Read-Through
Key Takeaway: Peer Q2 2026 earnings (reported July 14–30) paint a broadly constructive picture for SOLV’s end markets: hospital procedure volumes are stable-to-strong, capital spending remains healthy, tariff refunds are providing EPS tailwinds for peers (a potential upside SOLV has not guided for), and medtech demand fundamentals remain durable. The one cautionary note is ISRG’s observation of ACA/Medicaid-driven softness in deferrable procedures, which has limited read-through to SOLV’s higher-acuity wound care and infection prevention portfolio.
Note: All peer commentary below is from Q2 2026 earnings calls and releases (reported July 14–30, 2026), reflecting commentary about the same calendar quarter SOLV is now reporting. MDT commentary is from their fiscal Q4 2026 (ended April 24, 2026) — included for macro/medtech demand read-through only.
Theme 1: Hospital Procedure Volumes & Medtech Demand
Peer | Date | Commentary | SOLV Read-Through |
Stryker (SYK) | Jul 30, 2026 | "The US procedural environment remained stable. While there has been some commentary on softness in surgical volumes, particularly in discretionary procedures, we have not observed meaningful changes in volume trends." Portfolio is "highly diversified, with the vast majority of our businesses supporting high acuity, medically necessary and emergent care where clinical demand remains strong." | Positive read-through for SOLV’s MedSurg (wound care, infection prevention) — both are high-acuity, non-deferrable categories. Stable hospital volumes support IPSS and Advanced Wound Care demand. |
GE HealthCare (GEHC) | Jul 29, 2026 | "We’re seeing healthy end market demand in all three of our segments and across geographies." PDX (contrast agents) doing "extremely well." No pullback observed from customer surveys. "We haven’t really seen any pullback from surveys that we’ve done out there." | Broadly positive for medtech demand environment. Healthy hospital activity supports SOLV’s MedSurg and Dental segments. |
Intuitive Surgical (ISRG) | Jul 16, 2026 | U.S. Da Vinci procedure growth moderated to 12% (vs. expectations), "predominantly in procedures that can be deferred." ACA premium subsidy expiration had "modest adverse impact." Bariatric cases declined high single digits due to GLP-1 usage. International procedures grew 20%. | Limited negative read-through for SOLV — SOLV’s wound care and infection prevention are non-deferrable. Dental could see modest softness if patient coverage dynamics worsen, but SOLV’s Dental is more professional/restorative than elective. |
Medtronic (MDT) | Jun 3, 2026 | "MedTech is structurally resilient because the fundamentals are durable. People are living longer, chronic disease is rising and the demand for medical procedures will only grow." Delivered 6.6% organic growth in fiscal Q4 2026 — "strongest top line performance in 10 years." | Positive macro read-through. Durable demand fundamentals support SOLV’s multi-year organic growth acceleration thesis. |
Theme 2: Hospital Capital Spending & Customer Budgets
Peer | Date | Commentary | SOLV Read-Through |
Stryker (SYK) | Jul 30, 2026 | "We exited the quarter with an elevated backlog and expect continued strength in the hospital capital environment through the remainder of the year." Zero cancellations in order books. Record Mako sales month. "We’re just not seeing any issues related to capital equipment." | Positive for SOLV’s HIS segment (software contracts) and MedSurg capital-adjacent products. Strong hospital budgets support contract renewals and new module adoption in HIS. |
Baxter (BAX) | Jul 30, 2026 | "In the U.S., we have not observed any change in hospital capital spending" and order book reflects "solid demand." "We have not seen a massive change in behavior and buying behavior" from customers. Closely monitoring ACA/Medicaid impact but no material change observed. | Neutral-to-positive. Stable hospital spending environment supports SOLV’s HIS contract renewals and MedSurg consumables demand. |
GE HealthCare (GEHC) | Jul 29, 2026 | Secured rate on equipment entering Q3 is "nearly 85%," up several percentage points vs. prior quarters. Orders grew 11% with book-to-bill of 1.15x at record levels. Backlog grew $2.6B YoY to record $23.9B. | Positive macro signal. Record order backlog and high secured rates suggest hospital budgets remain intact, supporting SOLV’s HIS multi-year contract pipeline. |
Theme 3: Tariff Headwinds & Potential Refunds
Peer | Date | Commentary | SOLV Read-Through |
Boston Scientific (BSX) | Jul 29, 2026 | Recognized ~$80M of refunds on previously paid IEEPA tariffs in Q2, representing "substantially all of the refunds that we expect to receive." This was a non-recurring benefit. | Key upside risk for SOLV: SOLV has NOT assumed any tariff refunds in guidance ($100–$120M annual headwind fully embedded). If SOLV receives refunds similar to peers, this could be a meaningful EPS upside surprise in Q2. |
Intuitive Surgical (ISRG) | Jul 16, 2026 | Q2 results included a $36M pre-tax benefit from refund of previously paid IIPA tariffs. Excluding this, Q2 non-GAAP gross margin would have been 68.7% vs. reported 69.3%. | Same read-through as BSX — tariff refunds are materializing across medtech peers. SOLV’s guidance conservatism (no refunds assumed) creates potential upside. |
GE HealthCare (GEHC) | Jul 29, 2026 | Adjusted EBIT included $23M in recognized tariff refunds from Q1 2026. Free cash flow included $107M in tariff refunds. "The year over year impact of tariffs was neutral when including the benefit of refunds." | Consistent pattern across large medtech peers — tariff refunds are a sector-wide tailwind in Q2. SOLV’s conservative guidance stance makes this a potential positive surprise. |
Stryker (SYK) | Jul 30, 2026 | Experienced a "net benefit in the quarter from tariff related costs" which contributed to adjusted gross margin of 66% (+60 bps vs. Q2 2025). Stryker also noted a "Reversal of 2025 tariffs" of $(158)M in operating income. | Broad-based tariff reversal/refund trend across medtech. SOLV’s $100–$120M annual headwind assumption may prove conservative if refunds materialize. |
Baxter (BAX) | Jul 30, 2026 | Q2 included a $75M tariff refund contributing ~$0.11/share, "not initially contemplated in guidance." Even without this benefit, margins and earnings still surpassed expectations. H2 tariff impact expected at ~$40M net of mitigating actions. | Reinforces the tariff refund theme. BAX’s experience shows refunds can be material EPS drivers even for companies with smaller tariff exposures than SOLV. |
Theme 4: Organic Growth Trends & Macro Environment
Peer | Date | Commentary | SOLV Read-Through |
Stryker (SYK) | Jul 30, 2026 | Delivered 9% organic growth in Q2 2026, narrowed full-year guidance to 8.3–9.3% organic. "Fundamental drivers of healthcare demand remain firmly in place, including an aging population, the ongoing need for hospital workforce productivity, and the increasing occurrence of chronic disease." | Strong medtech demand backdrop. SOLV’s 3–5% organic growth target looks conservative relative to peers growing 7–9%, though SOLV is earlier in its commercial transformation. |
Boston Scientific (BSX) | Jul 29, 2026 | Q2 organic growth of 7% beat guidance of 5–7%. However, lowered full-year organic guidance to 5–6% (from higher) due to WATCHMAN and EP-specific headwinds. "Market conditions have evolved quickly and has been challenged to forecast effectively." | Mixed read-through. BSX’s guidance cut is product-specific (WATCHMAN, EP) with no relevance to SOLV’s categories. The Q2 beat itself is a positive signal for medtech demand broadly. |
GE HealthCare (GEHC) | Jul 29, 2026 | 3.5% organic growth in Q2, maintained full-year guidance of 3–4% organic. "Healthy end market demand in all three of our segments and across geographies." Expects >300 bps margin expansion from H1 to H2 driven by price/cost actions. | Neutral read-through on growth rate (GEHC is a different business mix). The H1-to-H2 margin expansion dynamic is directly analogous to SOLV’s guided operating margin improvement from Q1’s 19.5% seasonal low. |
Edwards Lifesciences (EW) | Jul 23, 2026 | Q2 sales growth of 12.5% YoY, raised full-year guidance to 10–11% total company growth. "TAVR average selling prices were stable globally." Reaffirmed long-term target of 10% average annual sales growth. | Positive macro signal for medtech demand. EW’s structural heart focus has limited direct read-through to SOLV, but the strong demand environment and pricing stability are broadly constructive. |
Medtronic (MDT) | Jun 3, 2026 | Guided FY27 organic growth of 6.75–7.25%, with "roughly 1-point headwind from increased fuel and transportation costs due to the conflict in the Middle East." Wound Management delivered "high single-digit growth" in fiscal Q4 2026. | Direct positive read-through: MDT’s Wound Management growing high single digits is a strong signal for SOLV’s Advanced Wound Care segment. Middle East logistics headwind is a risk SOLV management has also flagged. |
Theme 5: Health Information Systems, AI & Software
Peer | Date | Commentary | SOLV Read-Through |
Stryker (SYK) | Jul 30, 2026 | Stryker’s "Smartcare" business (Vocera + Care AI) saw elevated capital demand with increased backlog and strong orders. "The orders have really, really picked up since we’ve created the business unit, integrated the tech stack." Expecting "a very strong second half of the year and future" for Smartcare sales growth. | Positive read-through for SOLV’s HIS segment. Hospital demand for clinical workflow software and AI-enabled tools is accelerating. Validates SOLV’s autonomous coding and RCM growth thesis. |
GE HealthCare (GEHC) | Jul 29, 2026 | "We lead the industry in bringing AI to customers, and we’re also equally focused on using AI inside the company to improve productivity, simplify work, and strengthen our supply chain." AI-enabled NPIs in MRI and CT driving higher margins. "There’s not been one product that we’ve introduced that hasn’t come out at a higher value than its predicate." | Positive for SOLV’s HIS AI strategy. Peers are successfully monetizing AI at premium pricing — supports SOLV’s autonomous coding upsell thesis where customers pay more for AI-driven coding that reduces their FTE costs. |
Baxter (BAX) | Jul 30, 2026 | HST (Health Care Systems & Technology) segment grew 4% in Q2, with Care & Connectivity Solutions up 5% driven by patient support systems. Frontline Care grew 2%. HST adjusted operating margin was 20.3%, flat YoY. "Connects 360 continues to resonate well with customers." | Moderate positive read-through. Hospital technology spending is growing steadily. BAX’s 4–5% growth in healthcare IT is consistent with SOLV’s HIS segment guidance of ~4% growth for 2026. |
Theme 6: Margin Expansion & Cost Restructuring
Peer | Date | Commentary | SOLV Read-Through |
Boston Scientific (BSX) | Jul 29, 2026 | Announced a restructuring program targeting ~$500M in run-rate savings exiting 2029, covering supply chain optimization, functional transformation, org structure evolution, and indirect spending reductions. Adjusted operating margin expansion now guided at 0–25 bps for FY2026 (reduced from prior guidance). | Neutral read-through. BSX’s restructuring is a response to product-specific headwinds (WATCHMAN, EP). SOLV’s own Transform for the Future ($500M savings program) is already underway and more advanced. SOLV’s margin expansion story is not dependent on BSX-style reactive restructuring. |
GE HealthCare (GEHC) | Jul 29, 2026 | Expects >300 bps of margin expansion from H1 to H2 2026, driven by price/cost actions implemented in Q2. "Historically we see from the first half to second half about two and a half percentage points of margin improvement. Now interestingly, we’ll do a little bit better than that this year." | Directly analogous to SOLV’s guided H1-to-H2 margin improvement. SOLV’s Q1 operating margin was 19.5% (seasonal low); full-year guidance of 21–21.5% implies significant H2 improvement. GEHC’s experience validates this seasonal pattern. |
Medtronic (MDT) | Jun 3, 2026 | "Disciplined pricing provided 30 basis points benefit" to gross margin in fiscal Q4. COGS efficiency programs delivered "material savings, improved efficiencies and higher yields." FY27 operating margin guided up 60 bps driven by operating leverage. | Positive read-through. Programmatic savings and pricing discipline are delivering margin benefits across medtech — consistent with SOLV’s own programmatic savings program that drove Q1 gross margin outperformance. |
Theme 7: Supply Chain & Macro Risks
Peer | Date | Commentary | SOLV Read-Through |
Stryker (SYK) | Jul 30, 2026 | Supply disruptions in peripheral vascular (Inari) resulted in "meaningful backorder situation with lost sales in the quarter." Issue addressed; backorders expected at manageable level by end of Q3. Also managing "pressures on oil and other raw materials." | Neutral. SYK’s supply issue is product-specific (one plant). SOLV has already demonstrated supply chain improvement (backorder reduction highlighted as a key operational metric). Oil/raw material pressure is a shared risk SOLV has flagged but said is manageable in 2026. |
GE HealthCare (GEHC) | Jul 29, 2026 | Patient Care Solutions faced "operational fulfillment challenges" including "shortage of critical components." Memory chips continued to increase (more modestly). Oil "remains elevated, it is down a bit from the previous peak." $250M inflation assumption still appropriate. | Moderate risk read-through. GEHC’s component shortage is specific to monitoring/anesthesia. Oil elevated but declining from peak — consistent with SOLV management’s view that oil is not a material 2026 impact given fixed-price contracts and inventory timing. |
Medtronic (MDT) | Jun 3, 2026 | Embedded "roughly 1-point headwind from increased fuel and transportation costs due to the conflict in the Middle East" in FY27 guidance. Acknowledged colleagues in the Middle East impacted by the ongoing conflict. | Risk read-through for SOLV. SOLV management addressed Middle East exposure at KeyBanc, noting minimal direct infrastructure but flagging that sustained elevated oil prices could create logistics/raw material headwinds in 2027. MDT’s explicit 1-point headwind quantification is a useful benchmark. |